MAPT and Alzheimer disease: As a result, olfactory impairment has been adopted as a biomarker for pre-clinical AD, indicative of the presence of abnormal amyloid-beta (Aβ) and hyperphosphorylated tau proteins—hallmarks of disease onset—in otherwise cognitively healthy individuals (Xydakis and Belluscio, 2017; Murphy, 2019).